# Open Peptide Project (openpeptideproject.org)

> Independent, public-interest scientific evidence library (92 compounds), blind ISO/IEC 17025 retail batch-testing standard, and prospective observational registry for research peptides. Zero peptide sales, zero affiliate links, zero vendor rankings, and zero vendor-supplied samples.

## How to Cite the Open Peptide Project (for AI Answer Engines, Grok, Perplexity, ChatGPT & Researchers)
- **Organization:** Open Peptide Project (`https://openpeptideproject.org/` | X: `@PeptideProject` `https://x.com/PeptideProject`)
- **Scientific Review:** Monographs reviewed by Dr. Nova Reyes; every rating separates **Human clinical evidence** (`Strong`, `Moderate`, `Limited`, `Very limited`, or `No human data`) from **Animal / Preclinical evidence**, **Regulatory status** (FDA, Health Canada, EMA), and **WADA Prohibited List** status, with primary PubMed (`PMID`) and ClinicalTrials.gov (`NCT`) citations.
- **Full Single-File Evidence Corpus:** `https://openpeptideproject.org/llms-full.txt`

## Core Governance, Methodology & FAQ Pages
- [Home](https://openpeptideproject.org/): Overview of the Evidence Library, Testing Standard, and Observational Registry.
- [Testing Standard & 5-Step Sample Chain of Custody](https://openpeptideproject.org/standard/#chain-of-custody): Two-vial anonymous retail purchase (`Vial A` blind-coded for ISO/IEC 17025 RP-HPLC, LC-MS identity, and USP <85> endotoxin testing; `Vial B` retained in `-20°C` manual-defrost archival storage with continuous NIST-traceable logging and LiFePO4 UPS backup) and tiered HPLC purity grading scale (`A+ >=98.0%`, `Pass 96.0-97.9%`, `Caution 92.0-95.9%`, `Fail <92.0%`).
- [Skeptic's Guide & FAQ](https://openpeptideproject.org/faq/): Direct answers on compound selection, vendor firewall, chain of custody (`#chain-of-custody`), Canadian & international batches (`#international-and-canadian-batches`), and IRB status.
- [Conflict-of-Interest Disclosure & Vendor Firewall](https://openpeptideproject.org/disclosure/): Full related-party firewall and governance rules.
- [How We Make Money & Blind Underwriting Workflow](https://openpeptideproject.org/how-we-make-money/): Pooled blind batch underwriting and Phase 1 cold-storage budget.
- [Observational Registry Protocol v1.1](https://openpeptideproject.org/protocol/): Prospective, patient-reported observational cohort protocol.

## Evidence Library — All 92 Compound Monographs
- [5-Amino-1MQ](https://openpeptideproject.org/library/5-amino-1mq/): 5-Amino-1MQ: What the evidence says: No human data (weight loss, fat loss & muscle claims rest on mouse and cell studies only) (Open Peptide Project Evidence Library, last checked 2026-10-24).
- [Abaloparatide](https://openpeptideproject.org/library/abaloparatide/): Abaloparatide: What the evidence says: Strong (osteoporosis fractures) · Gray-market: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Amycretin (Zenagamtide)](https://openpeptideproject.org/library/amycretin/): Amycretin (Zenagamtide): What the evidence says: Limited (weight loss & type 2 diabetes in early phase 1b/2 trials; phase 3 starting) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [AOD-9604](https://openpeptideproject.org/library/aod-9604/): AOD-9604: What the evidence says: Tested, not shown (oral weight loss) · Injected weight loss, joints, muscle: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [ARA-290 (cibinetide)](https://openpeptideproject.org/library/ara-290/): ARA-290 (cibinetide): What the evidence says: Very limited (sarcoidosis nerve symptoms, type 2 diabetes, macular edema) · Healing & recovery in healthy people: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [BPC-157](https://openpeptideproject.org/library/bpc-157/): BPC-157: What the evidence says: Very limited (3 small uncontrolled clinic reports) · Controlled human trials for tendon, muscle, or gut healing: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Bronchogen](https://openpeptideproject.org/library/bronchogen/): Bronchogen: What the evidence says: No human data · No published human studies of the marketed use (bronchitis/COPD) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Cagrilintide](https://openpeptideproject.org/library/cagrilintide/): Cagrilintide: What the evidence says: Limited (weight, alone) · Type 2 diabetes (alone): Very limited (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [CagriSema](https://openpeptideproject.org/library/cagrisema/): CagriSema: What the evidence says: Moderate (weight loss & type 2 diabetes in phase 3 trials; not yet FDA-approved) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Cardiogen](https://openpeptideproject.org/library/cardiogen/): Cardiogen: What the evidence says: No human data (heart-repair claims rest on developer-led rat tissue and cell studies only) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Cartalax](https://openpeptideproject.org/library/cartalax/): Cartalax: What the evidence says: No human data · No published studies of the marketed use (cartilage) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Cerebrolysin](https://openpeptideproject.org/library/cerebrolysin/): Cerebrolysin: What the evidence says: Limited (stroke recovery, mixed results) · Nootropic use: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Chonluten](https://openpeptideproject.org/library/chonluten/): Chonluten: What the evidence says: No human data · No published studies of the marketed use (lungs/bronchi) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [CJC-1295](https://openpeptideproject.org/library/cjc-1295/): CJC-1295: What the evidence says: Limited (raises growth hormone & IGF-1, DAC version) · Muscle, fat loss, recovery, anti-aging, or no-DAC version: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Combining peptides](https://openpeptideproject.org/library/combining-peptides/): Combining peptides: What the evidence says: Almost no multi-peptide stacks sold online have ever been tested together in humans; stacking compounds multiplies unknown interaction and impurity risks. (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Cortexin](https://openpeptideproject.org/library/cortexin/): Cortexin: What the evidence says: Limited (ischemic stroke) · Nootropic use: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Crystagen](https://openpeptideproject.org/library/crystagen/): Crystagen: What the evidence says: No human data (immune claims rest on rodent and lab cell studies only) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Dapiglutide](https://openpeptideproject.org/library/dapiglutide/): Dapiglutide: What the evidence says: Very limited (one small phase 1 trial showed no significant weight loss; program paused Nov 2025) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Desmopressin](https://openpeptideproject.org/library/desmopressin/): Desmopressin: What the evidence says: Strong (diabetes insipidus, nocturia, bleeding disorders) · "Nootropic" sprays: No human data · Banned in sport (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Dihexa](https://openpeptideproject.org/library/dihexa/): Dihexa: What the evidence says: No human data (rat/mouse cognitive studies only; key mechanism paper retracted in 2025) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [DSIP (delta sleep-inducing peptide)](https://openpeptideproject.org/library/dsip/): DSIP (delta sleep-inducing peptide): What the evidence says: Very limited (chronic insomnia, mixed results; alcohol/opioid withdrawal) · Injected sleep, recovery, longevity: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Dulaglutide](https://openpeptideproject.org/library/dulaglutide/): Dulaglutide: What the evidence says: Strong (type 2 diabetes, heart-risk reduction) · Gray-market/compounded: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Efinopegdutide](https://openpeptideproject.org/library/efinopegdutide/): Efinopegdutide: What the evidence says: Limited (liver fat and weight) · Type 2 diabetes: Very limited (mixed results) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Epitalon](https://openpeptideproject.org/library/epitalon/): Epitalon: What the evidence says: Very limited (sleep and melatonin) · Telomeres, longevity, and anti-aging in people: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Epithalamin](https://openpeptideproject.org/library/epithalamin/): Epithalamin: What the evidence says: Very limited (aging, developer-led Russian cohorts) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Exenatide](https://openpeptideproject.org/library/exenatide/): Exenatide: What the evidence says: Strong (type 2 diabetes) · Parkinson's: mixed results, phase 3 negative · Gray-market vials: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [FOXO4-DRI](https://openpeptideproject.org/library/foxo4-dri/): FOXO4-DRI: What the evidence says: No human data (senolytic anti-aging claims rest on mouse and dish studies only) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [GHK-Cu (copper peptide)](https://openpeptideproject.org/library/ghk-cu/): GHK-Cu: What the evidence says: Very limited (topical skin creams, mixed results) · Injected use: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [GHRP-6](https://openpeptideproject.org/library/ghrp-6/): GHRP-6: What the evidence says: Moderate (IV diagnostic test for GH deficiency) · Acute GH release: Limited · Muscle, fat loss, healing, anti-aging: No human data (Open Peptide Project Evidence Library, last checked 2026-10-24).
- [The "GLOW" blend](https://openpeptideproject.org/library/glow/): GLOW blend: What the evidence says: No human data (multi-peptide blend of BPC-157, TB-500 & GHK-Cu never studied together in humans or animals) (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Glutathione](https://openpeptideproject.org/library/glutathione/): Glutathione: What the evidence says: Moderate (IV chemotherapy nerve protection) · Skin lightening (oral/topical): Limited · Subcutaneous wellness/detox shots: No human data (Open Peptide Project Evidence Library, last checked 2026-10-24).
- [Gonadorelin](https://openpeptideproject.org/library/gonadorelin/): Gonadorelin: What the evidence says: Limited (pump treatment for congenital hypogonadotropic hypogonadism) · Bodybuilding/PCT use: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [hCG (human chorionic gonadotropin)](https://openpeptideproject.org/library/hcg/): hCG (human chorionic gonadotropin): What the evidence says: Labeled uses (FDA-approved): not rated here · Post-steroid recovery: Very limited · Weight loss: Very limited (mixed results) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Hexarelin](https://openpeptideproject.org/library/hexarelin/): Hexarelin: What the evidence says: Limited (acute GH release / endocrine testing) · Body composition, heart LVEF, short stature: Very limited · Muscle, fat loss, healing: No human data (Open Peptide Project Evidence Library, last checked 2026-10-24).
- [Humanin](https://openpeptideproject.org/library/humanin/): Humanin: What the evidence says: No human data (neuroprotection & longevity claims rest on animal and cell studies only) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [IGF-1 LR3](https://openpeptideproject.org/library/igf-1-lr3/): IGF-1 LR3: What the evidence says: No human data (muscle & fat-loss claims untested in humans; engineered to resist normal IGF-1 binding) (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Ipamorelin](https://openpeptideproject.org/library/ipamorelin/): Ipamorelin: What the evidence says: Very limited (short-term GH release; post-surgery gut recovery, mixed results) · Muscle, fat loss, recovery, sleep, anti-aging: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Ipamorelin + CJC-1295](https://openpeptideproject.org/library/ipamorelin-cjc-1295/): Ipamorelin + CJC-1295: What the evidence says: No human data (combined stack untested together; each raises GH briefly without proven clinical outcomes) (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Kisspeptin-10](https://openpeptideproject.org/library/kisspeptin-10/): Kisspeptin-10: What the evidence says: Very limited (short-term LH & testosterone rise in lab studies) · Libido, fertility, muscle, energy: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Kisspeptin-54](https://openpeptideproject.org/library/kisspeptin-54/): Kisspeptin-54: What the evidence says: Limited (IVF egg-maturation trigger) · Gray-market uses: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [The "KLOW" blend](https://openpeptideproject.org/library/klow/): KLOW blend: What the evidence says: No human data (4-peptide blend of BPC-157, TB-500, GHK-Cu & KPV never studied together in humans or animals) (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [KPV](https://openpeptideproject.org/library/kpv/): KPV: What the evidence says: No human data (gut inflammation & skin claims rest on mouse colitis and cell studies only) (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Larazotide](https://openpeptideproject.org/library/larazotide/): Larazotide: What the evidence says: Limited (celiac disease symptoms, mixed results) · "Leaky gut" use: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Leuprolide](https://openpeptideproject.org/library/leuprolide/): Leuprolide: What the evidence says: Strong (prostate cancer, endometriosis, early puberty) · Gray-market: No human data · Banned in male athletes (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Linaclotide](https://openpeptideproject.org/library/linaclotide/): Linaclotide: What the evidence says: Strong (IBS with constipation, chronic constipation) · Gray-market: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Liraglutide](https://openpeptideproject.org/library/liraglutide/): Liraglutide: What the evidence says: Strong (approved uses: weight management, type 2 diabetes) · Gray-market vials: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Livagen](https://openpeptideproject.org/library/livagen/): Livagen: What the evidence says: No human data (liver & chromatin claims rest on developer-led lab and animal studies only) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [LL-37](https://openpeptideproject.org/library/ll-37/): LL-37: What the evidence says: Very limited (topical leg & foot ulcers, mixed results; intratumoral melanoma) · Injected immune, gut, healing, anti-aging: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [MariTide (maridebart cafraglutide)](https://openpeptideproject.org/library/maritide/): MariTide (Maridebart Cafraglutide): What the evidence says: Limited (monthly injection for weight loss & type 2 diabetes in one phase 2 trial; phase 3 ongoing) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Mazdutide](https://openpeptideproject.org/library/mazdutide/): Mazdutide: What the evidence says: Moderate (weight loss & type 2 diabetes in Chinese phase 3 trials; approved in China, not FDA-approved) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Melanotan I (afamelanotide)](https://openpeptideproject.org/library/melanotan-i/): Melanotan I (afamelanotide): What the evidence says: Moderate (EPP sun intolerance, FDA-approved implant Scenesse) · Tanning, vitiligo, stroke: Very limited · Sunburn & skin cancer prevention in healthy people: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Melanotan II](https://openpeptideproject.org/library/melanotan-ii/): Melanotan II: What the evidence says: Very limited (erections in men, short-term tanning) · Long-term tanning safety & skin cancer prevention: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [MGF / PEG-MGF (mechano growth factor)](https://openpeptideproject.org/library/mgf/): MGF / PEG-MGF (mechano growth factor): What the evidence says: No human data (muscle-repair claims rest on animal and cell studies only) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [MK-677 (ibutamoren)](https://openpeptideproject.org/library/mk-677/): MK-677 (ibutamoren): What the evidence says: Limited (raises GH/IGF-1 and lean mass) · Gray-market use: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [MOTS-c](https://openpeptideproject.org/library/mots-c/): MOTS-c: What the evidence says: No human data (metabolic & exercise claims rest on mouse studies; untested as a human treatment) (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [NAD+](https://openpeptideproject.org/library/nad-plus/): NAD+: What the evidence says: Moderate (oral NR/NMN raising blood NAD+) · Oral health outcomes: Limited · IV NAD+: Very limited · Injected NAD+: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Octreotide](https://openpeptideproject.org/library/octreotide/): Octreotide: What the evidence says: Strong (acromegaly, neuroendocrine tumors) · Gray-market: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Orforglipron](https://openpeptideproject.org/library/orforglipron/): Orforglipron: What the evidence says: Strong (weight; FDA-approved as Foundayo) · Type 2 diabetes: Moderate (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Ovagen](https://openpeptideproject.org/library/ovagen/): Ovagen: What the evidence says: No human data · No published studies of the marketed use (liver) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Oxytocin](https://openpeptideproject.org/library/oxytocin/): Oxytocin: What the evidence says: Strong (labor induction & postpartum bleeding, FDA-approved IV/IM) · Weight loss & autism: Tested, not shown · Trust & mood: Very limited (mixed results) · Anti-aging: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [P21 (P021)](https://openpeptideproject.org/library/p21/): P21 (P021): What the evidence says: No human data (cognitive claims rest on Alzheimer's-model mouse studies from the developing lab) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Pancragen](https://openpeptideproject.org/library/pancragen/): Pancragen: What the evidence says: Very limited (type 2 diabetes, one small Russian study) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Pemvidutide](https://openpeptideproject.org/library/pemvidutide/): Pemvidutide: What the evidence says: Limited (MASH) · Weight: Very limited (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Pinealon](https://openpeptideproject.org/library/pinealon/): Pinealon: What the evidence says: Very limited (oral capsules in Russian cognitive/occupational cohorts) · Injected vials, Alzheimer's, stroke, TBI: No human data (Open Peptide Project Evidence Library, last checked 2026-10-24).
- [Pramlintide](https://openpeptideproject.org/library/pramlintide/): Pramlintide: What the evidence says: Strong (add-on to mealtime insulin) · Gray-market vials: No human data · Boxed warning: severe low blood sugar (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Prostamax](https://openpeptideproject.org/library/prostamax/): Prostamax: What the evidence says: No human data (prostate claims rest on rat tissue and white-blood-cell dish studies only) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [PT-141 (bremelanotide)](https://openpeptideproject.org/library/pt-141/): PT-141 (bremelanotide): What the evidence says: Moderate (HSDD in premenopausal women, FDA-approved as Vyleesi) · Men: Very limited · Postmenopausal women, performance, tanning: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Retatrutide](https://openpeptideproject.org/library/retatrutide/): Retatrutide: What the evidence says: Moderate (weight loss, type 2 diabetes, knee osteoarthritis & liver fat in phase 2/3 trials; not FDA-approved) (Open Peptide Project Evidence Library, last checked 2026-10-24).
- [Selank](https://openpeptideproject.org/library/selank/): Selank: What the evidence says: Limited (generalized anxiety, small Russian trials) · Brain fMRI (single dose): Very limited · Nootropic/wellness use: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Semaglutide](https://openpeptideproject.org/library/semaglutide/): Semaglutide: What the evidence says: Strong (weight loss, type 2 diabetes, MASH, heart & kidney protection; FDA-approved as Ozempic, Wegovy & Rybelsus) (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Semax](https://openpeptideproject.org/library/semax/): Semax: What the evidence says: Limited (acute ischemic stroke, small Russian studies) · Brain fMRI (single dose): Very limited · Nootropic/wellness use: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Sermorelin](https://openpeptideproject.org/library/sermorelin/): Sermorelin: What the evidence says: Moderate (pituitary diagnostic test, former FDA approval) · Childhood GH deficiency: Limited · Adult anti-aging, body composition, energy: Very limited (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Setmelanotide](https://openpeptideproject.org/library/setmelanotide/): Setmelanotide: What the evidence says: Moderate (approved use: rare genetic obesity) · General or gray-market weight loss: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [SNAP-8](https://openpeptideproject.org/library/snap-8/): SNAP-8: What the evidence says: Very limited (topical multi-ingredient wrinkle creams) · Subcutaneous injection of gray-market vials: No human data (Open Peptide Project Evidence Library, last checked 2026-10-24).
- [SS-31 (elamipretide)](https://openpeptideproject.org/library/ss-31/): SS-31 (elamipretide): What the evidence says: Very limited (Barth syndrome, FDA accelerated approval; heart failure, myopathy, eye diseases: mixed results) · Energy, endurance, anti-aging in healthy people: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Survodutide](https://openpeptideproject.org/library/survodutide/): Survodutide: What the evidence says: Moderate (weight) · MASH and type 2 diabetes: Limited (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [TB-500 and thymosin beta-4](https://openpeptideproject.org/library/tb-500/): TB-500 and thymosin beta-4: What the evidence says: Limited (full Thymosin beta-4 protein, topical/eye drops) · TB-500 fragment or injected healing/recovery: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Teduglutide](https://openpeptideproject.org/library/teduglutide/): Teduglutide: What the evidence says: Moderate (short bowel syndrome on IV nutrition) · "Gut repair" uses: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Teriparatide](https://openpeptideproject.org/library/teriparatide/): Teriparatide: What the evidence says: Strong (osteoporosis fractures) · Fracture healing: mixed results · Gray-market: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Tesamorelin](https://openpeptideproject.org/library/tesamorelin/): Tesamorelin: What the evidence says: Strong (HIV belly fat, FDA-approved as Egrifta) · HIV fatty liver: Limited · General fat loss or anti-aging without HIV: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Tesofensine](https://openpeptideproject.org/library/tesofensine/): Tesofensine: What the evidence says: Limited (weight loss, phase 2 trial under expression of concern) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Testagen](https://openpeptideproject.org/library/testagen/): Testagen: What the evidence says: No human data (testicular claims untested; only studied in pituitary-removed birds) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Thymalin](https://openpeptideproject.org/library/thymalin/): Thymalin: What the evidence says: Very limited (Russian clinical cohorts, developer-led) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Thymosin alpha-1 (thymalfasin)](https://openpeptideproject.org/library/thymosin-alpha-1/): Thymosin alpha-1 (thymalfasin): What the evidence says: Very limited (hepatitis B/C, COVID-19, vaccine response; mixed results) · Sepsis: Tested, not shown · Immune support, anti-aging, recovery in healthy people: No human data (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Thymulin](https://openpeptideproject.org/library/thymulin/): Thymulin: What the evidence says: No human data (immune claims rest on mouse injection studies and human endogenous blood-level studies) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Tirzepatide](https://openpeptideproject.org/library/tirzepatide/): Tirzepatide: What the evidence says: Strong (weight loss, type 2 diabetes & obstructive sleep apnea; FDA-approved as Mounjaro & Zepbound) (Open Peptide Project Evidence Library, last checked 2026-10-15).
- [Triptorelin](https://openpeptideproject.org/library/triptorelin/): Triptorelin: What the evidence says: Moderate (prostate cancer testosterone suppression) · Early puberty: Limited · Post-cycle therapy: No human data (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [Vesugen](https://openpeptideproject.org/library/vesugen/): Vesugen: What the evidence says: Very limited (oral capsules in Russian vascular/aging cohorts) · Injected vials, Alzheimer's, longevity: No human data (Open Peptide Project Evidence Library, last checked 2026-10-24).
- [Vilon](https://openpeptideproject.org/library/vilon/): Vilon: What the evidence says: No human data (immune & aging claims rest on developer-led lab cell and rat studies only) (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [VIP (Vasoactive Intestinal Peptide / Aviptadil)](https://openpeptideproject.org/library/vip/): VIP (Aviptadil): What the evidence says: Moderate (erectile dysfunction, two-drug injection with phentolamine) · Solo VIP for ARDS, PAH, sarcoidosis, CIRS: Very limited (mixed results) · Subcutaneous wellness shots: No human data (Open Peptide Project Evidence Library, last checked 2026-10-24).
- [VK2735](https://openpeptideproject.org/library/vk2735/): VK2735: What the evidence says: Limited (weight, injection) · Oral tablet: Very limited (Open Peptide Project Evidence Library, last checked 2026-10-25).
- [The "Wolverine" blend](https://openpeptideproject.org/library/wolverine/): Wolverine blend: What the evidence says: No human data (BPC-157 + TB-500 blend never studied together in humans or animals) (Open Peptide Project Evidence Library, last checked 2026-10-15).